Physician

Mark Byron Jennings, MD

According to 2025 Medicare claims, Mark Jennings, MD (NPI: 1336379783) practices hematology/oncology in the Tulsa, OK market, with the plurality of this provider's patient population coming from Tulsa, OK. This provider's primary affiliated billing organization is OKLAHOMA CANCER SPECIALISTS AND RESEARCH INSTITUTE LLC (NPI: 1962876045; TIN: 383983999) and primary practice location at 74146-6236. Jennings is affiliated with the Lifecare ACO LLC (ACO ID: A3644), participating under the MSSP model.

Jennings' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,069 traditional Medicare patients, billed 170,397 HCPCS/CPT codes, and received $3,216,453 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 2,398 prescription claims across 308 beneficiaries totaling $5,994,930 in drug costs, led by Imbruvica (Ibrutinib). DME data shows 22 claims. Open Payments data shows 40 records totaling $738. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $382,900 to $3,216,453. Similarly, Part D prescription costs have risen steadily, from $19,892 to $5,994,930. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $406 to $1,255.